Arythmies fœtales : diagnostic, pronostic, traitement ; à propos de 33 cas

Vautier-Rit, S.; Dufour, P; Vaksmann, Guy; Subtil, D.; Vaast, P.; Valat, Anne-Sylvie; Dubos, J. P.; Puech, F

doi:10.1016/s1297-9589(00)00003-5

Cited by 9 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our initial search yielded 93 titles and abstracts, 19 full-text articles were retained for manual review 4,7,[13][14][15][17][18][19][20][21]38,[68][69][70][71][72][73][74][75] ( Figure 1). This represented a total of 495 cases of fetal SVT, 107 of which had hydrops fetalis.…”

Section: Current Practices and Maternal Outcomesmentioning

confidence: 99%

Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia

et al. 2018

View full text Add to dashboard Cite

Fetal tachycardia is a rare complication during pregnancy. After exclusion of maternal and fetal conditions that can result in a secondary fetal tachycardia, supraventricular tachycardia is the most common cause of a primary sustained fetal tachyarrhythmia. In cases of sustained fetal supraventricular tachycardia, maternal administration of digoxin, flecainide, sotalol, and more rarely amiodarone, is considered. As these medications have the potential to cause significant adverse effects, we sought to examine maternal safety during transplacental treatment of fetal supraventricular tachycardia. In this narrative review we summarize the literature addressing pharmacologic properties, monitoring, and adverse reactions associated with medications most commonly prescribed for transplacental therapy of fetal supraventricular tachycardia. We also describe maternal monitoring practices and adverse events currently reported in the literature. In light of our findings, we provide clinicians with a suggested maternal monitoring protocol aimed at optimizing safety.

show abstract

Section: Current Practices and Maternal Outcomesmentioning

confidence: 99%

Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia

et al. 2018

View full text Add to dashboard Cite

show abstract

“…It successfully controlled arrhythmia in 85 (78.7%) of them. There were 8 (7.4%) cases of sudden fetal death in four reports [1,7,8,11].…”

Section: Authorsmentioning

confidence: 98%

Amiodarone in Treatment of Fetal Supraventricular Tachycardia

et al. 2005

View full text Add to dashboard Cite

We report a case of nonimmune hydrops fetalis detected at 32 weeks of gestation. Fetal heart rate was 300 beats per minute. Ultrasound and fetal Doppler echocardiography showed it to be due to supraventricular tachycardia (SVT). Following failed maternal therapy with digoxin alone, amiodarone with digoxin was used. Conversion to sinus rhythm and resolution of hydrops followed this treatment. Since there is no ideal treatment protocol for these cases at present, we reviewed reports of transplacental treatment of SVT.

show abstract

“…82 It is especially useful in treating cases refractory to digoxin and in those complicated by hydrops fetalis. 83 Although the majority of reported cases have good outcomes, caution is still advised with flecainide use because of the reports of death of 3 fetuses, 82,84 including one that died 15 minutes after transplacental administration. 82 None of these deaths, however, could be attributed with certainty to the drug.…”

Section: Class Ic Antiarrhythmics Flecainidementioning

confidence: 99%

Cardiovascular Pharmacotherapeutic Considerations During Pregnancy and Lactation

Qasqas

McPherson²,

Frishman³

et al. 2004

Cardiology in Review

View full text Add to dashboard Cite

Cardiovascular drugs are often used in pregnancy for the treatment of maternal and fetal conditions. Mothers could also require continued postpartum drug therapy. Most cardiovascular drugs taken by pregnant women can cross the placenta and therefore expose the developing embryo and fetus to their pharmacologic and teratogenic effects. These effects are influenced by the intrinsic pharmacokinetic properties of a given drug as well as by the complex physiological changes occurring during pregnancy. Many drugs are also transferred into human milk and therefore can potentially have adverse effects on the nursing infant. This 2-part article summarizes some of the available literature concerning the risks and benefits of using various cardiovascular drugs and drug classes during pregnancy and lactation. Included in the discussion are cardiac glycosides, antiarrhythmic drugs, drugs used to treat both acute and chronic hypertension, cholesterol-lowering agents, anticoagulants, thrombolytics, and antiplatelet drugs.

show abstract

Arythmies fœtales : diagnostic, pronostic, traitement ; à propos de 33 cas

Cited by 9 publications

References 19 publications

Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia

Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia

Amiodarone in Treatment of Fetal Supraventricular Tachycardia

Cardiovascular Pharmacotherapeutic Considerations During Pregnancy and Lactation

Contact Info

Product

Resources

About